Mi­cro­cap can­cer play­er goes bel­ly up af­ter pan­cre­at­ic tu­mor hope­ful flops key study

TYME Tech­nolo­gies’ SM-88 has been pulled from a Phase II/III study af­ter a clin­i­cal tri­al spon­sor clued the biotech in on an ex­pect­ed fail­ure for fu­til­i­ty against stan­dard-of-care chemo in pa­tients with metasta­t­ic pan­cre­at­ic can­cer, the com­pa­ny said Wednes­day.

Through the Pan­cre­at­ic Can­cer Ac­tion Net­work, TYME said a com­bi­na­tion of SM-88 — a mod­i­fied ty­ro­sine de­riv­a­tive the com­pa­ny be­lieves breaks down tu­mors’ meta­bol­ic process­es — and a reg­i­men known as MPS was ex­pect­ed to un­der­per­form chemo in terms of ex­tend­ing pa­tients’ lives. The study test­ed that com­bo against chemo reg­i­mens in­clud­ing gem­c­itabine and Abrax­ane or mod­i­fied FOLFIRI­NOX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER